



Translated from Russian

INDEPENDENT AUDITOR'S REPORT

To the Shareholders of Limited Liability Company «UNIQUE PHARMACEUTICAL LABORATORIES».

Opinion

We have audited the accompanying financial (accounting) statements of LLC "UNIQUE PHARMACEUTICAL LABORATORIES" (OGRN 1057746834420, address: 127994, Moscow, Tverskaya st. 18, building 1, office 609), for the period from April 1st, 2018 to March 31st, 2019, which comprise the balance sheet statement as of March 31st, 2019, statement of comprehensive income.

In our opinion, the accompanying financial (accounting) statements present fairly, in all material respects, the financial position of LLC «UNIQUE PHARMACEUTICAL LABORATORIES» as at March 31st, 2019, and its financial performance for the period from April 1st, 2018 to March 31st, 2019 in accordance with the accounting principles generally accepted in the Russian Federation.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our report. We are independent of the audited entity in accordance with Rules of Independence of Auditors and Audit Organizations and Code of Professional Ethics for Auditors that comply with Code of Ethics for Professional Accountants, developed by The International Ethics Standards Board for Accountants, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter – Basis of Accounting and Restriction on Distribution

We draw attention to the fact, that the financial (accounting) statements are prepared for presentation to owners of "UNIQUE PHARMACEUTICAL LABORATORIES" LLC information, concerning activities of "UNIQUE PHARMACEUTICAL LABORATORIES" LLC for the period from April 1st, 2018 to March 31st, 2019. As a result, the financial (accounting) statements may not be suitable for other purposes. Our opinion is not modified in respect of this matter.

Responsibilities of Management for the financial (accounting) statements

Management is responsible for the preparation and fair presentation of the financial (accounting) statements in accordance with the accounting principles generally accepted in the Russian Federation, and for such internal control as management determines is necessary to enable the preparation of financial (accounting) statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial (accounting) statements, management is responsible for assessing the audited entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the audited entity or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the financial (accounting) statements

Our objectives are to obtain reasonable assurance about whether the financial (accounting) statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial (accounting) statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

a) identify and assess the risks of material misstatement of the financial (accounting) statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;

b) obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the

purpose of expressing an opinion on the effectiveness of the audited entity's internal control;

c) evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;

d) conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the audited entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial (accounting) statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the audited entity to cease to continue as a going concern;

e) evaluate the overall presentation, structure and content of the financial (accounting) statements, including the disclosures, and whether the financial (accounting) statements represent the underlying transactions and events in a manner that achieves fair presentation.

General Director of
LLC «Alinga Consulting»



/Alexander Kulikov/

Auditor:

Limited Liability Company «Alinga Consulting»,

OGRN (State Registration Number): 1107746908356,

Russian Federation, 105066, Moscow, Niznaya Krasnoselskaya St. 35, corp. 64,
premise I, part of room 23A,

Member of Self-regulated organization of auditors – "Russian Union of auditors"
(Association) (RUA),

Registration number (ORNZ) 11003031033

April 26, 2019

BALANCE SHEET
as on 31 March 20 19

Organization LLC «UNIQUE PHARMACEUTICAL LABORATORIES»
Taxpayer Identification Number (INN) _____

Form OKUD
Date (year, month, day) _____
OKPO
INN

Type of economical activity Wholesale trade OKVED
Form of incorporation/form of ownership Limited Liability Company/
Owned by foreign legal entity OKOPF/OKFS
Measuring unit: thousand Rubles OKEI
Location (address) 127994, Moscow, Tverskaya str.,18, bldg. 1,office 609

CODES		
0710001		
31	03	2019
77474688		
7703550219		
46.18.1		
65		23
384		

Explanation s	Indicator name	Code	As on 31 st Mar 20 19 r. ³	As on 31st Mar 20 18 r. ⁴	As on 31st Mar 20 17 r. ⁵
	ASSETS				
	I. NON-CURRENT ASSETS				
	Intangible assets	1110	-	-	-
	Research and investigation results	1120	-	-	-
	Intangible search assets	1130	-	-	-
	Tangible search assets	1140	-	-	-
	Fixed assets	1150	12 340	12 226	8 711
	Income-bearing lease investments	1160	-	-	-
	Financial investments	1170	-	-	-
	Deferred tax assets	1180	62 490	64 824	65 200
	Other non-current assets	1190	1 306	1 418	1 539
	Section I TOTAL	1100	76 136	78 468	75 450
	II. CURRENT ASSETS				
	Inventories	1210	177 133	211 658	162 226
	Value added tax on acquired assets	1220	4 499	14 854	12 820
	Accounts receivable	1230	292 494	329 924	242 898
	Financial investments (without cash equivalent)	1240	20 000	15 000	20 000
	Cash and cash equivalent	1250	8 491	3 539	6 927
	Other current assets	1260	185	118	192
	Section II TOTAL	1200	502 802	575 093	445 063
	BALANCE	1600	578 938	653 561	520 513

Explanation s	Indicator name	Code	As on 31 st Mar 20 19 r. ³	As on 31st Mar 20 18 r. ⁴	As on 31st Mar 20 17 r. ⁵
	LIABILITIES				
	III. EQUITY AND RESERVES ⁶				
	Authorized capital (share capital, charter fund, contributions of partners)	1310	365 265	365 265	365 265
	Contributions of shareholders	1311	-	-	-
	Shares repurchased	1320	(-)	(-)	(-)
	Re-value of intangible assets	1340	-	-	-
	Additional capital (without re-value)	1350	-	-	-
	Reserve funds	1360	-	-	-
	Undistributed profits (uncovered loss)	1370	- 188 791	- 207 975	- 217 236
	Section III TOTAL	1300	176 474	157 290	148 029
	IV. LONG-TERM LIABILITIES				
	Loans and credits	1410	-	-	-
	Deferred tax liabilities	1420	1	1	1
	Evaluation liabilities	1430	-	-	-
	Other long-term liabilities	1450	-	-	-
	Section IV TOTAL	1400	1	1	1
	V. SHORT-TERM LIABILITIES				
	Loans and credits	1510	-	-	-
	Accounts payable	1520	385 267	480 344	358 082
	Deferred income	1530	-	-	-
	Evaluation liabilities	1540	17 196	15 926	14 401
	Other short-term liabilities	1550	-	-	-
	Section V TOTAL	1500	402 463	496 270	372 483
	BALANCE	1700	578 938	653 561	520 513

Head of the organization

" 26 " April 20 19 r.



(Signature)

Nasa Sandeep

(Print name)



STATEMENT OF COMPREHENSIVE INCOME

for 01 April 2018 - 31 March 2019

Organization LLC «UNIQUE PHARMACEUTICAL LABORATORIES»
 Taxpayer Identification Number (INN) _____

Form OKUD
 Date (year, month, day) _____
 OKPO
 INN

Type of economical activity Wholesale trade
 Form of incorporation/form of ownership Limited Liability Company /
Owned by foreign legal entity
 Measuring unit: thousand Rubles

OKVED
 OKOPF/OKFS
 OKEI

Codes		
0710002		
31	03	2019
77474688		
7703550219		
46.18.1		
65	23	
384		


Explanations	Indicator name	Code	April 2018 - March 2019	April 2017 - March 2018
	Income ⁵	2110	858 866	758 705
	Cost of goods sold	2120	(788 047)	(704 861)
	Gross profit (loss)	2100	70 819	(53 844)
	Commercial expenses	2210	(44 280)	(47 025)
	Administrative expenses	2220	(-)	(-)
	Sales profit (loss)	2200	26 539	6 819
	Income from participation in other organizations	2310	-	-
	Interest receivable	2320	1 131	1 701
	Interest payable	2330	(-)	(-)
	Other incomes	2340	4 221	11 369
	Other losses	2350	(7 295)	(8 272)
	Profit (loss) before tax	2300	24 596	11 617
	Current profit tax	2410	(3 078)	(1 980)
	including Constant tax liabilities (assets)	2421	493	33
	Change of deferred tax liabilities	2430	-	-
	Change of deferred tax assets	2450	(2 334)	(376)
	Other	2460	-	-
	Net profit (loss)	2400	19 184	9 261

Form 0710002 p. 2

Explanations	Indicator name	Code	April 2018 - March 2019	April 2017 - March 2018
	FOR REFERENCE ONLY			
	Result from re-valuation of intangible assets not included into Net profit (loss) of the period	2510	-	-
	Result from other operations not included into Net profit (loss) of the period	2520	-	-
	Total financial result of the period ⁶	2500	19 184	9 261
	Basic earnings (loss) per share	2900	-	-
	Diluted earnings (loss) per share	2910	-	-

Head of the organization

" 26 " April 20 19



Nasa Sandeep
 (Signature)

Nasa Sandeep
 (Print name)

OOO UNIQUE PHARMACEUTICAL LABORATORIES

(0)

0

BALANCE SHEET AS AT 31ST MAR 2019

In Roubles

SOURCES OF FUNDS

Equity Capital		365 264 639
Share capital under registration		-
Reserves and Surplus		(188 791 120)
Current Liabilities		402 463 761
Deferred tax liabilities		823
TOTAL		578 938 103

APPLICATION OF FUNDS

Fixed Assets	44 318 424	
Less : Accumulated Dep	31 978 096	
Net Assets		12 340 328
Deferred tax assets		62 490 165
<u>Current Assets, Loans and Advances</u>		
Inventory		177 133 416
Debtors		284 502 737
Loans and Advances		
Advances to suppliers	2 944 424	
Other Advances	1 167 580	
VAT refund receivable	4 631 172	
Other taxes	9 032	
Prepaid expenses	3 968 279	
Advances to Staff	1 259 877	
Cash and Bank		13 980 365
Deposit	20 000 000	
Cash	-	
USD Account	60 880	
RUR Account	8 430 212	
		28 491 092

TOTAL

578 938 103

For LLC Alinga Consulting

For and on behalf of the company

General Director
Alexander Kurkov

Sandeep Nasa
General Director



Moscow : 26th Apr 2019



000 UNIQUE PHARMACEUTICAL LABORATORIES

PROFIT & LOSS ACCOUNT FOR FINANCIAL APR18-MAR19

INCOME

A	Net Sales	626 465 400
B	Other Incomes/Expenses	
	Interest on bank deposits	1 131 151
	Foreign exchange gain	(591 679)
	Other Income	270 979 554
	Total Income	897 984 426

EXPENDITURE

Cost of Goods Sold	518 189 598
Shortages/Damages	377 266
Packing	427 630
Warehousing expenses	10 960 111
Salary	12 926 707
Social Taxes	3 328 704
Medical insurance	371 385
Freight Expenses	656 524
Audit Fees	-
HR expenses	29 400
Certification	211 912
Insurance	517 662
Licensing Expenses	-
Staff Welfare Expenses	289 425
Office Rent	5 387 188
Consulting services	2 216 419
Bank Charges	1 728 992
Software expenses	731 868
Depreciation	774 459
Destruction expenses	145 690
Marketing expenses	260 078 779
Bonuses for distributors	35 290 557
Discounts, compensations of shortages/damages	8 853
Loss on DNs	51 992
Reserve on vacation	9 778 730
Reserve on bad debts	-
Other	491 065
Apprt. Rent for HQS (subject for profit tax base)	414 198
Apprt. Rent for HQS (not subject for profit tax base)	1 194 558
Loss on assignment of claim	-
Fixed assets retirement	-
Allowance for impaire of inventory	-
Miscellaneous Expenses	4 555 921

Total Expenditure

873 388 427

Profit/(Loss) Before Tax

24 596 000

Income Tax-Current

(3 078 237)

Income Tax-Deferred

(2 333 637)

Other

Profit/(Loss) After Tax

19 184 126

(Balance carried to Balance Sheet)

For LLC Alinga Consulting

General Director
Alexandra Kuznetsov


For and on behalf of the company

Sandeep Nasa
 General Director

Moscow : 26th Apr 2019



OOO UNIQUE PHARMACEUTICAL LABORATORIES

FIXED ASSETS AS AT 31ST MAR 2019

Fixed Assets

Description of Assets	Gross block as on 01Apr18	Addition during the year	Deduction during the year	Gross block as on 31Mar19	Depreciation as on 01Apr18	Depreciation for the year	Deduction during the year	Depreciation as on 31Mar19	Net block as on 31Mar19	Net block as on 01Apr18
Computers	1 645 918	1 430 906	-	3 076 824	964 159	691 222	-	1 655 381	1 421 443	681 759
Cars	40 264 689	4 079 931	3 730 723	40 613 898	28 825 360	4 576 413	3 684 980	29 716 793	10 897 105	11 439 329
Safe	26 878	-	-	26 878	12 898	1 169	-	14 067	12 811	13 980
Other	45 373	-	-	45 373	39 928	5 445	-	45 373	-	5 445
Air conditioners	254 782	-	-	254 782	236 369	18 413	-	254 782	(0)	18 413
Mini ATS	254 144	-	-	254 144	209 295	35 879	-	245 174	8 970	44 849
Projector	45 525	-	-	45 525	24 193	22 332	-	46 525	-	22 332
	42 538 309	5 510 837	3 730 723	44 318 424	30 312 203	5 350 873	3 684 980	31 978 096	12 340 328	12 226 106

For LLC Alinga Consulting

Alexander Kulikov



For and on behalf of the company

Sandeep Nasa

Moscow : 26th Apr 2019

